Patient Outcomes

Bayer Sues J&J Over Erleada Marketing, Alleging False Superiority Claims Versus Nubeqa

Filed in Manhattan under the Lanham Act, the case challenges J&J’s real-world study that promoted a 51% mortality advantage.